Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sertraline + alprazolam is a fixed-dose combination of two pharmaceutical agents used primarily in the treatment of panic disorder (with or without agoraphobia) and depression. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain, thereby improving mood, cognition, and memory. Alprazolam is a benzodiazepine that enhances the activity of gamma-aminobutyric acid (GABA), producing anxiolytic, muscle relaxant, and sedative effects. The combination targets both depressive symptoms and anxiety/panic attacks by modulating serotonergic neurotransmission (sertraline) and potentiating inhibitory GABAergic signaling (alprazolam)[5][8]. This dual mechanism provides symptomatic relief for patients with comorbid anxiety and depressive disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sertraline + alprazolam.